Although portions of tau protein within the microtubule binding region have been 9 shown to form the ordered core of tau filaments, the structural details of how other 10 regions of tau participate in filament formation are so far unknown. In an attempt to 11 understand how the N-terminus of tau may interact with fibril core, we crystallized and 12 determined the structure of the N-terminal segment 5RQEFEV10 of tau. Several lines of 13 evidence have shown the importance of this segment for fibril formation. The crystal 14 structure reveals an out-of-register Class 5 steric zipper with a wet and a dry interface.
that polar clasp, neighboring aromatic residues restrict the glutamines to a conformation 86 in which they bond to each other within a hydrophobic pocket (Figure 2 A) . As stated by The crystal structure of 5RQEFEV10 can account for the low resolution density 90 found in the cryo-EM reconstructions of Alzheimer's Disease (AD) tau filaments near 91 residues K317 and K321, much as suggested by Fitzpatrick, et al (12) . The positioning 92 of 5RQEFEV10 near these residues in the tau filament conformation is supported by the 93 binding of the MC-1 and Alz50 antibodies to a discontinuous epitope consisting of both 94 7EFE9 and 313VDLSKVTSKC322(17) .
95
In order to examine the potential interaction of the N-terminal 7EFE9 segment with 96 the AD fibril core, we first computationally docked the 6QEFEV10 segment seen in the 97 crystal structure into the low-resolution density shown to be adjacent to residues K317 98 and K321 in the AD Paired Helical Filament (PHF) (Figure 3 A-B) (12) . In this model, the 99 wet interface glutamates found in the crystal structure form electrostatic interactions with 100 the exposed lysines in the PHF fibril, while the dry interface faces away from the PHF 101 surface (Figure 3 A, B) . Notably, we omitted Arg5 in this model due to steric clashes 102 with Leu315 on the PHF. We speculate that Arg5 would have to adopt a different 103 conformation in the fibril structure than in the crystal structure in order to maintain the 104 interaction of Glu7 and Glu9 with Lys317 and Lys321.
105
To examine further the relevance of the 7EFE9 and 313VDLSKVTSKC322 106 interaction in tau fibrils, we searched the literature for other evidence that implicates the 107 N-terminus of tau in fibril formation. Poorkaj, P. et al. described a missense mutation 108 found in a Progressive Supranuclear Palsy (PSP) patient that changes R5 to a 109 leucine(23). In addition, it has been shown that deletion of residues 2-18 produces less 110 aggregated tau than the wild-type sequence whereas the inclusion of the R5L mutation 111 increases the amount of aggregated tau in the presence of arachidonic acid(24). This is 112 6 consistent with our model of 7EFE9 binding to 313VDLSKVTSKC322 in the AD PHF; in that 113 the deletion of residues 2-18 would abrogate the interaction of 7EFE9 with 114 313VDLSKVTSKC322. In addition, in our model the R5L mutation would result in a more 115 stable interaction with Leu315 as discussed below.
116
To analyze if the R5L mutation might affect the binding of 5RQEFEV10 to the 117 313VDLSKVTSKC322 region in the AD filaments, we modeled the putative interaction of 118 the sequence 5LQEFEV10 with the AD PHF. To accomplish this, we mutated the R5 that 119 was omitted in the wild-type model due a potential steric clash with L315 on the PHF, to 120 a rotamer of leucine that would maximize its buried surface area and shape 121 complementarity to L315 on the PHF (Figure 3 B) . The model demonstrates that the 122 mutation R5L would result in a more favorable interaction with the PHF than the native 123 sequence, providing an explanation for R5L's ability to increase tau aggregation.
124
Our attempts to dock the 5RQEFEV10 crystal structure into the 125 313VDLSKVTSKC322 region on the cryoEM structure of the straight filaments (SFs) were 126 hindered due to the tight packing protofilaments that occurs in this region. By truncating 127 the residues present in the crystal structure to only 7EFE9 it is possible to place these 128 residues within hydrogen bonding distance of K317 on one protofilament and K321 on 129 the other protofilament. This results in a binding site comprised of residues from two 130 different tau monomers, as opposed to a binding site comprised of only one monomer 131 as in the PHF ( Figure 3D ). However, this two-tau monomer model of 7EFE9 bound to the 132 SF would result in steric clashes if any other residues were added to the 7EFE9 133 sequence ( Figure 3D ), particularly with L315, making it harder to assess whether there Alz50, most likely bind a single epitope of tau comprised of discontinuous segments 142 7EFE9 and 313VDLSKVTSKC322. The idea of a single epitope comprising these two distal 143 sequences was supported by antibody binding assays using a series of tau constructs 144 containing truncations or mutations in these regions (19) . Tau constructs missing either 145 7EFE9 or 313VDLSKVTSKC322 did not exhibit antibody binding, demonstrating that both 146 sequences need to be present for antibody reactivity. In addition, a series of mutations 147 to the 7EFE9 segment (Glu7,9 -> Ala7,9; Phe8 -> Ser8) abrogated antibody binding to 148 tau. Importantly, Jicha, et al showed that tau constructs missing 7EFE9 or 149 313VDLSKVTSKC322 could not be mixed in solution to recover the MC-1/Alz50 epitope, 150 indicating that this epitope is formed intramolecularly.
151
In an attempt to examine which sequences might interact with the primary 152 nucleating sequences of tau 275VQIINK280 given that Phe8 is facing away from the fibril, allowing it to remain exposed for antibody 174 binding. Therefore, mutation of Phe8 may not prevent the far N-terminal segment from 175 binding to the exposed lysines on the fibril core, but may still eliminate antibody 176 reactivity. This suggests that the 7EFE9 segment needs to be not only in a stacked 177 conformation bound to K317 and K321 on the fibril core, but also needs F8 to be facing indicating the preservation of the 7EFE9 and 313VDLSKVTSKC322 epitope (14) . In this 204 structure, K317 and K321 are exposed to the solvent in a beta-sheet conformation, 205 which would allow the N-terminal 7EFE9 segment to bind K317 and K321 through 206 electrostatic interactions between the glutamates and lysines similar to the AD PHF 207 model (Figure 3 A, B) . This electrostatic interaction would preserve the MC-1 epitope 208 and provide an explanation for why MC-1 recognizes both tau fibril polymorphs.
209
In addition, the potential strengthening of the N-terminal interaction with the fibril 210 core through the R5L mutation and its discovery in a PSP patient, suggests that this 211 interaction may also occur in the PSP tau fibril. Although there is evidence that so-called 212 4R tauopathies, where the dominant species found in aggregated tau are the 4R 213 isoforms, PSP and Corticobasal Degeneration (CBD) form different tau polymorphs, 214 their structures have not yet been determined(25). However, as long as the 215 313VDLSKVTSKC322 region adopts a beta-sheet like fold, and K317 and K321 remain 216 solvent-exposed, the long-range charge-charge interaction with 7EFE9 could be 217 preserved. In short, there may be a common interaction among the disparate folds of 218 tau polymorphs.
219
In the past, our lab has developed inhibitors of tau aggregation by structure-220 based drug design (11, 16) . This requires detailed structural knowledge of a site of the 221 tau protein in the aggregated state obtained by X-ray crystallography or MicroED. These 222 inhibitors target segments of the tau protein in the microtubule binding region that is 223 thought to participate in the fibril core of all tau filaments. However, given the structural 224 evidence thus far that the microtubule binding region can adopt different folds in 225 different diseases, it is likely that a spectrum of inhibitors will be necessary to most 226 11 effectively block aggregation or spreading of specific tau polymorphs. Immuno-labeling 227 with MC-1 seems to indicate that the N-terminal interaction with the fibril core modeled 228 here is preserved in both AD and Pick's Disease tau filaments. Therefore, an inhibitor 229 targeted towards this interaction may be general to all tau filaments, providing another 230 target for treating tauopathies. Acknowledgments: 250 We thank Michael Sawaya for discussion and Michael Collazo at UCLA-DOE 251 Macromolecular Crystallization Core Technology Center for crystallization support. We with phenix.refine. Acta Crystallogr D Biol Crystallogr. 2012 Apr 1;68(4):352-67. Statistics for the highest-resolution shell are shown in parentheses
